BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,435,000 | -16.2% | 26,651 | -0.1% | 0.04% | -10.3% |
| Q2 2022 | $1,713,000 | -24.3% | 26,673 | -8.6% | 0.04% | -11.4% |
| Q1 2022 | $2,264,000 | -12.0% | 29,195 | -2.6% | 0.04% | -8.3% |
| Q4 2021 | $2,573,000 | -5.5% | 29,980 | -11.4% | 0.05% | 0.0% |
| Q3 2021 | $2,722,000 | -3.7% | 33,840 | -3.7% | 0.05% | +2.1% |
| Q2 2021 | $2,828,000 | -7.4% | 35,126 | -3.0% | 0.05% | -13.0% |
| Q1 2021 | $3,053,000 | +1.2% | 36,209 | -3.7% | 0.05% | +3.8% |
| Q4 2020 | $3,016,000 | -9.0% | 37,583 | -8.8% | 0.05% | -40.9% |
| Q3 2020 | $3,314,000 | -26.4% | 41,210 | -21.2% | 0.09% | -31.8% |
| Q2 2020 | $4,502,000 | -31.8% | 52,287 | -35.7% | 0.13% | -41.1% |
| Q1 2020 | $6,603,000 | -26.9% | 81,333 | -24.7% | 0.22% | -6.0% |
| Q4 2019 | $9,029,000 | -31.1% | 107,977 | -27.9% | 0.23% | -36.0% |
| Q3 2019 | $13,106,000 | +4.3% | 149,836 | -2.3% | 0.36% | +3.1% |
| Q2 2019 | $12,567,000 | -6.4% | 153,439 | -7.1% | 0.35% | -8.8% |
| Q1 2019 | $13,424,000 | +22.5% | 165,091 | -0.8% | 0.39% | +12.2% |
| Q4 2018 | $10,956,000 | -14.7% | 166,460 | -0.1% | 0.34% | -6.5% |
| Q3 2018 | $12,845,000 | +8.4% | 166,617 | +3.8% | 0.37% | +0.8% |
| Q2 2018 | $11,853,000 | +7.4% | 160,530 | -5.4% | 0.37% | +9.6% |
| Q1 2018 | $11,035,000 | -7.7% | 169,672 | -8.3% | 0.33% | -4.3% |
| Q4 2017 | $11,954,000 | -5.3% | 184,935 | -8.1% | 0.35% | -12.8% |
| Q3 2017 | $12,624,000 | +1.8% | 201,189 | -1.8% | 0.40% | +0.8% |
| Q2 2017 | $12,402,000 | +13.0% | 204,859 | -3.2% | 0.40% | +10.0% |
| Q1 2017 | $10,974,000 | +13.4% | 211,600 | -3.1% | 0.36% | +12.1% |
| Q4 2016 | $9,680,000 | -2.9% | 218,308 | +4.2% | 0.32% | -5.0% |
| Q3 2016 | $9,973,000 | +2.2% | 209,502 | -3.0% | 0.34% | -0.3% |
| Q2 2016 | $9,762,000 | +4.8% | 215,877 | -4.8% | 0.34% | +3.0% |
| Q1 2016 | $9,317,000 | +11.0% | 226,809 | +3.1% | 0.33% | +9.3% |
| Q4 2015 | $8,390,000 | +39.5% | 219,927 | +20.2% | 0.30% | +34.8% |
| Q3 2015 | $6,013,000 | -50.2% | 183,020 | +6.1% | 0.22% | -45.2% |
| Q2 2015 | $12,063,000 | +6.0% | 172,483 | +3.8% | 0.41% | +7.9% |
| Q1 2015 | $11,382,000 | -7.0% | 166,163 | -0.5% | 0.38% | -7.1% |
| Q4 2014 | $12,237,000 | +2.9% | 166,959 | +0.8% | 0.41% | +2.3% |
| Q3 2014 | $11,892,000 | -0.1% | 165,684 | +0.6% | 0.40% | +2.8% |
| Q2 2014 | $11,908,000 | +6.6% | 164,686 | +8.5% | 0.39% | +2.9% |
| Q1 2014 | $11,166,000 | +10.7% | 151,756 | +4.7% | 0.38% | +13.2% |
| Q4 2013 | $10,084,000 | -6.0% | 144,980 | -11.2% | 0.33% | -9.8% |
| Q3 2013 | $10,727,000 | -50.2% | 163,272 | -47.5% | 0.37% | -14.0% |
| Q2 2013 | $21,547,000 | +7.9% | 310,856 | +7.2% | 0.43% | +10.0% |
| Q1 2013 | $19,963,000 | +5.8% | 289,930 | +2.5% | 0.39% | +0.3% |
| Q4 2012 | $18,862,000 | +25.3% | 282,937 | +13.3% | 0.39% | +13.1% |
| Q3 2012 | $15,048,000 | +29.2% | 249,671 | +13.9% | 0.34% | +16.2% |
| Q2 2012 | $11,648,000 | +14.5% | 219,151 | +28.7% | 0.30% | +16.5% |
| Q1 2012 | $10,177,000 | +16.0% | 170,237 | -4.0% | 0.25% | +11.4% |
| Q4 2011 | $8,773,000 | -22.9% | 177,299 | -12.6% | 0.23% | -30.9% |
| Q3 2011 | $11,383,000 | -6.9% | 202,779 | -1.0% | 0.33% | +9.3% |
| Q2 2011 | $12,227,000 | +10.3% | 204,831 | -0.7% | 0.30% | +9.8% |
| Q1 2011 | $11,088,000 | +34.4% | 206,211 | +26.6% | 0.28% | +26.7% |
| Q4 2010 | $8,248,000 | – | 162,910 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |